As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

Overall, 503 patients received first-line TNF inhibitors, of whom 261 switched to upadacitinib, while 128 switched to another TNF inhibitor and 114 switched to another mechanism of action.

The incidence rate for cardiovascular events among patients exposed to TNF inhibitors was 8.92/10,000 person-years, 12.87/10,000 person-years for IL-17 inhibitor exposure, and 18.66/10,000 person ...

Kids with polyarticular-course juvenile idiopathic arthritis (JIA) who received a second tumor necrosis factor (TNF) inhibitor after failing one initially did just as well as those who changed to ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...